480 ARSENAL WAY, WATERTOWN, MA
Investor Presentation
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Other Events
Lyra Therapeutics' LYR-210 Shows Positive Phase 3 Results in CRS Treatment
Material disclosure
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload